Logo image
Back
Update on PET Imaging of Neuroendocrine Neoplasms
Journal article   Peer reviewed

Update on PET Imaging of Neuroendocrine Neoplasms

Charanjeet Singh, Mamta Gupta, Ananya Panda, Anjali Prakash, Joyce Mhlanga, Onofrio Antonio Catalano and Mayur K Virarkar
Seminars in ultrasound, CT, and MRI
06/05/2026
DOI: 10.1053/j.sult.2026.06.006
PMID: 42250739

View Online

Abstract

Positron emission tomography (PET) now complements ultrasound, CT, and MRI by enabling whole-body assessment of tumor biology in neuroendocrine neoplasms (NENs). Somatostatin receptor (SSTR) directed PET is the reference standard for staging, prognostication, and selection for peptide receptor radionuclide therapy (PRRT) in well-differentiated neuroendocrine tumors (NETs), while 18F-FDG PET identifies aggressive, dedifferentiated components that may be refractory to receptor-targeted strategies. Recent Society of Nuclear Medicine and Molecular Imaging/European Association of Nuclear Medicine (SNMMI/EANM) guidelines standardize SSTR PET/CT procedures and reporting. Emerging advances include fluorinated SSTR ligands (e.g., 18F-AlF-NOTA-octreotide, 18F-SiTATE), SSTR antagonists (JR11 family), copper-64 theranostics (64Cu-SARTATE), and non-SSTR targets such as GLP-1R, CXCR4, and FAP. Hybrid PET/MRI improves hepatic lesion characterization and reduces radiation in appropriate patients, while CT/MRI remains indispensable for morphology and complications. Integrating multi-tracer PET with anatomic imaging refines risk stratification, PRRT selection, and longitudinal response assessment.
 177Lu-DOTATATE PRRT 18F-FDG 64Cu-DOTATATE 68Ga-DOTANOC 68Ga-DOTATATE Neuroendocrine Tumors Neurondocrine neoplasms peptide receptor radionuclide therapy (PRRT) PET/CT PET/MRI Somatostatin receptor SSTR Theranostics

Details

Metrics

1 Record Views
Logo image